TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04583449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental imagery
Description: Mental imagery involves the mental representation of a future event, action, or task. By imitating or rehearsing this mental event or series of events (Taylor et al., 1998, p. 430) mental imagery interventionists theorise that an individual's preparation for, and motivation toward, a future action can be made more likely. Mental imagery involves an individual following a set of pre-defined exercises involving thinking about, visualising and writing about a health-related action. Mental imagery exercises can involve focusing on anticipated positive/beneficial outcomes of an action (outcome imagery) or imagery relating to the anticipated strategies/preparation that would be required to successfully execute a pre-defined action (process imagery).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental imagery
Description: Mental imagery involves the mental representation of a future event, action, or task. By imitating or rehearsing this mental event or series of events (Taylor et al., 1998, p. 430) mental imagery interventionists theorise that an individual's preparation for, and motivation toward, a future action can be made more likely. Mental imagery involves an individual following a set of pre-defined exercises involving thinking about, visualising and writing about a health-related action. Mental imagery exercises can involve focusing on anticipated positive/beneficial outcomes of an action (outcome imagery) or imagery relating to the anticipated strategies/preparation that would be required to successfully execute a pre-defined action (process imagery).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental imagery
Description: Mental imagery involves the mental representation of a future event, action, or task. By imitating or rehearsing this mental event or series of events (Taylor et al., 1998, p. 430) mental imagery interventionists theorise that an individual's preparation for, and motivation toward, a future action can be made more likely. Mental imagery involves an individual following a set of pre-defined exercises involving thinking about, visualising and writing about a health-related action. Mental imagery exercises can involve focusing on anticipated positive/beneficial outcomes of an action (outcome imagery) or imagery relating to the anticipated strategies/preparation that would be required to successfully execute a pre-defined action (process imagery).
Study: NCT00642694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10 or 20mg qd based on symptoms at patient visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10 or 20mg qd based on symptoms at patient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg qd

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo qd
Study: NCT02047175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/S-Amlodipine
Description: Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20mg 1T PO, QD for 5days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/S-Amlodipine + Rosuvastatin
Description: Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/S-Amlodipine + Rosuvastatin
Description: Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days
Study: NCT03514641

Intervention type: DRUG
Group type: OTHER
Intervention: Bexagliflozin
Description: Bexagliflozin tablet, 20 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Bexagliflozin
Description: Bexagliflozin tablet, 20 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Bexagliflozin
Description: Bexagliflozin tablet, 20 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Bexagliflozin
Description: Bexagliflozin tablet, 20 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo (inactive) tablet to match the active drug

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo (inactive) tablet to match the active drug

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo (inactive) tablet to match the active drug
Study: NCT04327713

Intervention type: DIETARY_SUPPLEMENT
Intervention: fish oil supplement
Description: daily fish oil supplement vs. placebo
Study: NCT03069508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemizole Hydrochloride
Description: Clemizole Hydrochloride will be administered orally for up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemizole Hydrochloride
Description: Clemizole Hydrochloride will be administered orally for up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemizole Hydrochloride
Description: Clemizole Hydrochloride will be administered orally for up to 24 weeks
Study: NCT02707679

Intervention type: OTHER
Group type: OTHER
Intervention: Kinesiotaping
Description: Kinesiotaping was applied on patient with patellofemoral pain syndrome. To maintain proprioceptive stimulation in the quadriceps (from origo towards insertio) and to alleviate the tension of hamstring muscle, a 'Y''-shaped kinesiotape was applied by using the muscle technique.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: All the patients were provided with several exercises within the scope of the home exercise program, such as hamstring muscle stretching, quadriceps isometric exercises, 4-way-strengthening with exercise elastic bands for the muscles of the hip, knee locking on foot and mini-squatting exercises. They were asked to do these exercises in 3 sets a day along with 10 repetitions for a period of 6 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: All the patients were provided with several exercises within the scope of the home exercise program, such as hamstring muscle stretching, quadriceps isometric exercises, 4-way-strengthening with exercise elastic bands for the muscles of the hip, knee locking on foot and mini-squatting exercises. They were asked to do these exercises in 3 sets a day along with 10 repetitions for a period of 6 weeks.
Study: NCT00605696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants will receive intravenous insulin to target tight glycemic control (80 to 110 mg/dL) for up to 48 hours after ICU admission.
Study: NCT02570113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peregrine System Infusion Catheter
Description: The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
Study: NCT01631175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychosocial treatment
Description: psychosocial treatment, verbal therapy, relaxation exercises
Study: NCT03377764

Intervention type: PROCEDURE
Intervention: Landmark Technique Control group
Description: Spinal Anesthetic

Intervention type: PROCEDURE
Intervention: Neuroaxial block using Ultrasound Guidance
Description: Ultrasound guided Spinal Anesthetic
Study: NCT02731417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture for women with post partum urinary retention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: Foley catheter insertion for women with post partum urinary retention.
Study: NCT00505375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTLA-4 Ig
Description: Intravenous infusion of 10 mg/kg of CTLA-4 Ig every other week for the first two doses and then every 28 days for a total of 27 doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusions of placebo every other week for the first two doses and then every 28 days for a total of 27 doses
Study: NCT03907384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mat Pilates training
Description: This group completed 12-weeks of training
Study: NCT01295294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 500 mg 3 times daily per oral during bleeding/spotting episodes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Description: 500 mg 3 times daily per oral during bleeding/spotting episodes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 times daily per oral during bleeding/spotting episodes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirena (Levonorgestrel IUS, BAY86-5028)
Description: In vitro release rate 20 microgram/24 hours. Intrauterine system

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirena (Levonorgestrel IUS, BAY86-5028)
Description: In vitro release rate 20 microgram/24 hours. Intrauterine system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirena (Levonorgestrel IUS, BAY86-5028)
Description: In vitro release rate 20 microgram/24 hours. Intrauterine system
Study: NCT00587600

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: Photofrin 2mg/kg Photoradiation The light dose delivered will be a total of 200 joules per centimeter fiber which has previously been shown to ablate Barrett's mucosa.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation of barrett's esophagus
Description: radiofrequency ablation
Study: NCT02715934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose to Goal
Description: The Glucose to Goal intervention applies elements of the Patient Centered Medical Home (i.e., practice design, decision support, population management, etc) to diabetes education services and operationalizes the current DSME objectives in the primary care setting.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The control group will follow the traditional DMSE delivery model, which includes primary care providers referring patients to an outpatient, hospital-based diabetes educator for DSME, but in a passive manner (i.e., without proactive patient identification), which is the usual process for referrals.
Study: NCT03230799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimal invasive lens surgery
Description: We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
Study: NCT00605696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participants will receive intravenous insulin to target tight glycemic control (80 to 110 mg/dL) for up to 48 hours after ICU admission.
Study: NCT02016222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tears sampling
Study: NCT03069508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemizole Hydrochloride
Description: Clemizole Hydrochloride will be administered orally for up to 24 weeks
Study: NCT03017105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-education of strength-training
Description: Strength-training exercises using isometric contractions and resistance bands to be performed with the uninjured arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual rehabilitation
Description: Exercises to improve range of movement, strength and movement control (as standard for non-operatively managed proximal humerus fractures)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual rehabilitation
Description: Exercises to improve range of movement, strength and movement control (as standard for non-operatively managed proximal humerus fractures)
Study: NCT00598819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDI 1000 COM
Description: CDI 1000 COM sensors were attached to subject's forehead for a 12 hour period.
Study: NCT04133025

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation
Description: Vestibular Exercises and Software in vestibular rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation
Description: Vestibular Exercises and Software in vestibular rehabilitation
Study: NCT01186250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 15mg pioglitazone taken daily for one month, 30mg pioglitazone taken daily for another month, 45mg pioglitazone taken daily for remaining ten months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo taken daily for one year
Study: NCT00368030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Eszopiclone 3 mg QD
Study: NCT02994381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC1063
Study: NCT04110860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole gel once daily
Description: voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole gel twice daily
Description: voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner
Study: NCT04709718

Intervention type: PROCEDURE
Intervention: hepatectomy
Description: liver resection taking over the liver hemangioma
Study: NCT00871091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthodontic treatment with customized archwires
Description: customized arch wires depending on the amount of needed tooth movement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic treatment with prefabricated archwires
Description: prefabricated archwires depending of the needed movement of the teeth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic tx w/ conventional archwires+manual adjustments
Description: conventional archwires modified by manual adjustment, depending of needed correction
Study: NCT00352313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-161
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-161
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT04359342

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HIIT + protein
Description: 8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: HIIT + placebo
Description: 8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HIIT and resistance training + protein
Description: 8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: HIIT and resistance training + placebo
Description: 8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session.
Study: NCT04565600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: Etoricoxib 60 Mg Oral Tablet
Study: NCT02661464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to Ad26.ZEBOV vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to MVA-BN-Filo vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
Study: NCT01367860

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open microdiscectomy
Description: The open microdiscectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Diskectomy SpineJet
Description: Percutaneous Diskectomy SpineJet be performed under local anesthesia, in which a needle is placed via percutaneous posterolateral extra-pedicular, below the neural foramen in the center of the disc, using the traditional approach for discography. The researcher will confirm the proper placement of the needle in front and side incidences on the fluoroscopy.
Study: NCT03579030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsule matched to an RTA 1701 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsule matched to an RTA 1701 capsule
Study: NCT00368030

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT01937520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: One half of subjects will receive a standardized acupuncture regiment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: no acupuncture
Description: placebo
Study: NCT02185534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)
Study: NCT03579030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 1701 capsules
Description: Capsule containing RTA 1701, multiple dosages

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 1701 capsules
Description: Capsule containing RTA 1701, multiple dosages
Study: NCT03954977

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PICC line ultrasound
Description: NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.
Study: NCT01634945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP/amodiaquine
Description: One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FeFum fortified porridge
Description: 6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP/Amodiaquine + FeFum fortified porridge
Description: One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.~6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate fortified porridge
Description: 6 days per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferric pyrophosphate) for 9 months.
Study: NCT02185534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)
Study: NCT04236089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic hand
Description: mirror therapy with robotic hand
Study: NCT01634945

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of SP/Amodiaquine every 3 months for 9 months. No dietary intervention.
Study: NCT02467855

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention was administered in this study.

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention was administered in this study.